Hepatocellular CarcinomaPhase 2NCT04567615
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
A Phase 2 study testing Nivolumab and Relatlimab in people with Hepatocellular Carcinoma and Hepatoma, run by Bristol-Myers Squibb at 65 sites in 17 countries.
Trial summary
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult
- What is being tested?
- Nivolumab and Relatlimab
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 266 participants
- Where
- 65 sitesin 17 countries
- Study dates
- 4 Feb 2021to 19 Nov 2025
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must have a diagnosis of hepatocellular carcinoma (HCC) based on histological confirmation
- Must have advanced/metastatic HCC
- Have to be immunotherapy treatment-naive in the advanced/metastatic setting
- Must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measurable untreated lesion
- Child-Pugh score of 5 or 6
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 for ECOG performance status scale
Who cannot join
- Known fibrolamellar HCC, sarcomatoid HCC, combined hepatocellular cholangiocarcinoma
- Prior organ allograft or allogeneic bone marrow transplantation
- No uncontrolled or significant cardiovascular disease
- No active known autoimmune disease
- Have received one or two lines of tyrosine kinase inhibitor therapies
- Evidence of radiographic progression on or after the last line of tyrosine kinase inhibitor therapy
- Other protocol-defined inclusion/exclusion criteria apply
Trial locations and contacts
65 sites in 17 countries.
65 sites in 17 countries
China6 sites
Local Institution - 0114
Changsha, Hunan, 410013
Local Institution - 0117
Hangzhou, Zhejiang, 310016
Local Institution - 0113
Harbin, Heilongjiang, 150081
Local Institution - 0107
Shanghai, Shanghai Municipality, 200032
Local Institution - 0118
Xi'an, Shaanxi, 710061
Local Institution - 0108
Xi'an, Shan3xi, 710126
Japan6 sites
Local Institution - 0075
Ishikawa, 920-8641
Local Institution - 0071
Kyoto, 602-8566
Local Institution - 0072
Matsuyama, Ehime, 790-0024
Local Institution - 0045
Ōsaka-sayama, Osaka, 589-8511
Local Institution - 0054
Yokohama, Kanagawa, 232-0024
Local Institution - 0076
Yokohama, Kanagawa, 241-8515
Spain6 sites
Local Institution - 0066
Barcelona, 08036
Local Institution - 0073
Córdoba, 14004
Local Institution - 0050
Donostia / San Sebastian, Gipuzkoa, 20014
Local Institution - 0051
Madrid, 28009
Local Institution - 0049
Madrid, 28041
Local Institution - 0058
Pamplona, 31008
Brazil5 sites
Local Institution - 0016
Barretos, São Paulo, 14784400
Local Institution - 0025
Belo Horizonte, Minas Gerais, 30130-090
Local Institution - 0060
Porto Alegre, Rio Grande do Sul, 91350-200
Unidade de Pesquisa Clínica do Hospital da Clínicas de Ribeirão Preto-Clinical Oncology
Ribeirão Preto, São Paulo, 14051-140
Local Institution - 0015
São Paulo, São Paulo, 01246-000
France5 sites
Local Institution - 0068
Clichy, 92110
Local Institution - 0105
Grenoble, 38043
Local Institution - 0074
Lyon, 69004
Local Institution - 0067
Pessac, 33600
Local Institution - 0069
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54511
Taiwan5 sites
Local Institution - 0041
Taichung, 40447
Local Institution - 0034
Tainan, 704
Local Institution - 0031
Taipei, 100
Local Institution - 0042
Taipei, 11217
Local Institution - 0032
Taoyuan, 333
Argentina4 sites
Local Institution - 0019
Buenos Aires, Distrito Federal, C1096AAS
Local Institution - 0010
Ciudad de Buenos Aires, Buenos Aires, 1181
Local Institution - 0017
Rosario, Santa Fe Province, S2002KDS
Local Institution - 0063
San Miguel de Tucumán, Tucumán Province, 4000
Poland4 sites
Local Institution - 0012
Bytom, 41-900
Local Institution - 0013
Krakow, Lesser Poland Voivodeship, 31-501
Local Institution - 0009
Mysowice, 41-400
Local Institution - 0039
Warsaw, 02-034
Romania4 sites
Local Institution - 0037
Bucharest, 022328
Local Institution - 0036
Cluj-Napoca, 400015
Local Institution - 0038
Craiova, Dolj, 200542
Local Institution - 0070
Suceava, 720214
Chile3 sites
Local Institution - 0029
Santiago, Santiago Metropolitan, 000000
Local Institution - 0018
Santiago, Santiago Metropolitan, 8420383
Local Institution - 0024
Temuco, Araucania, 4800827
Czechia3 sites
Local Institution - 0048
Brno, 65653
Local Institution - 0047
Hradec Králové, 50005
Local Institution - 0046
Prague, 140 59
Mexico3 sites
Local Institution - 0100
Cuauhtémoc, 06700
Local Institution - 0106
Oaxaca City, 68020
Local Institution - 0101
San Luis Potosí City, San Luis Potosí, 78250
South Korea3 sites
Local Institution - 0020
Seongnam-si, 13496
Local Institution - 0011
Seoul, Seoul-teukbyeolsi, 05505
Local Institution - 0043
Seoul, 06351
Turkey (Türkiye)3 sites
Local Institution - 0089
Ankara, 06230
Local Institution - 0090
Edirne, 22030
Local Institution - 0091
Kadiköy/Istanbul, 41380
Hong Kong2 sites
Local Institution - 0077
Hksar, 0
Local Institution - 0079
Shatin, 0
Singapore2 sites
Local Institution - 0001
Singapore, Central Singapore, 168583
Local Institution - 0004
Singapore, 308433
About this study
Official title: A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult
- Being tested
- Nivolumab, Relatlimab
- Keywords
- Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Liver Cancer, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult
- Medical subject headings
- Carcinoma, Hepatocellular, Liver Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NivolumabBiological
Also called OPDIVO, BMS-936558
Specified dose on specified days
RelatlimabBiological
Also called BMS-986016
Specified dose on specified days
| Study group | Role | What they receive |
|---|---|---|
| Arm A : Nivolumab | Experimental | Not described Receives: Biological: Nivolumab |
| Arm B : Nivolumab + Relatlimab Dose 1 | Experimental | Not described Receives: Biological: Nivolumab; Biological: Relatlimab |
| Arm C : Nivolumab + Relatlimab Dose 2 | Experimental | Not described Receives: Biological: Nivolumab; Biological: Relatlimab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response Rate(ORR) Assessed by BICR
Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments among all participants in the respective analysis set.
BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first.
For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Secondary outcomes (14)
Disease Control Rate Assessed by BICR
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Duration of Response Assessed by BICR
Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR, or death due to any cause, whichever occurs first.
Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Progression Free Survival(PFS) Assessed by BICR
PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first.
Participants who die without a reported progression will be considered to have progressed on the date of their death.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Objective Response Rate Assessed by Investigator
Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on investigator assessments among all participants in the respective analysis set.
BOR is defined as the best response, as determined by the investigator, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first.
For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Disease Control Rate Assessed by Investigator
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Duration of Response Assessed by Investigator
Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the investigator, or death due to any cause, whichever occurs first.
Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Progression Free Survival(PFS) Assessed by Investigator
PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first.
Participants who die without a reported progression will be considered to have progressed on the date of their death.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Overall Survival (OS)
Overall survival (OS) is defined as the time from randomization to the date of death from any cause.
Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Number of Participants With Adverse Events
Number of participants with an Adverse Event.
An Adverse Event is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Measured: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Number of Participants With Serious Adverse Events
Number of participants with Serious Adverse Events
A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
Measured: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Number of Participants With Adverse Events Leading to Discontinuation
Number of participants with Adverse Events Leading to Discontinuation
Measured: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Death Summary
Number of participants who died.
Measured: From randomization to primary completion date (Approximately 29.5 Months)
Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests
Number of participants with clinical laboratory abnormalities in specific liver tests
Measured: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Number of Participants With Clinical Laboratory Abnormalities in Thyroid Tests
Number of participants with clinical laboratory abnormalities in thyroid tests
Measured: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2020
- Study start4 Feb 2021
- Primary completion31 Aug 2023
- Study completion19 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 266 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04567615
- Sponsor's protocol ID
- CA224-073
- Other IDs
- 2018-003151-38, U1111-1218-6499, 2018
- Status last verified
- Dec 2025
- First submitted
- 24 Sep 2020
- Last updated
- 8 Jan 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
- ClinicalTrials.gov ID
- NCT04567615
- Acronym / sponsor ID
- CA224-073
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult
- Keywords
- Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Liver Cancer, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 266 participants (actual)
- Lead sponsor
- Bristol-Myers SquibbIndustry (pharma, biotech, devices)
- Study start
- 4 Feb 2021 (actual)
- Primary completion
- 31 Aug 2023 (actual)
- Study completion
- 19 Nov 2025 (actual)
- First posted
- 28 Sep 2020 (actual)
- Results
- Posted 8 Oct 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm A : Nivolumab | Experimental | Biological: Nivolumab |
| Arm B : Nivolumab + Relatlimab Dose 1 | Experimental | Biological: Nivolumab, Biological: Relatlimab |
| Arm C : Nivolumab + Relatlimab Dose 2 | Experimental | Biological: Nivolumab, Biological: Relatlimab |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Must have a diagnosis of hepatocellular carcinoma (HCC) based on histological confirmation
- Must have advanced/metastatic HCC
- Have to be immunotherapy treatment-naive in the advanced/metastatic setting
- Must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measurable untreated lesion
- Child-Pugh score of 5 or 6
Key exclusion criteria (7 listed)
- Known fibrolamellar HCC, sarcomatoid HCC, combined hepatocellular cholangiocarcinoma
- Prior organ allograft or allogeneic bone marrow transplantation
- No uncontrolled or significant cardiovascular disease
- No active known autoimmune disease
- Have received one or two lines of tyrosine kinase inhibitor therapies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NivolumabAlso: OPDIVO, BMS-936558Specified dose on specified days | Biological | Arm A : Nivolumab, Arm B : Nivolumab + Relatlimab Dose 1, Arm C : Nivolumab + Relatlimab Dose 2 |
| RelatlimabAlso: BMS-986016Specified dose on specified days | Biological | Arm B : Nivolumab + Relatlimab Dose 1, Arm C : Nivolumab + Relatlimab Dose 2 |
Primary outcome
Objective Response Rate(ORR) Assessed by BICR
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments among all participants in the respective analysis set. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.
14 secondary outcomes
Disease Control Rate Assessed by BICR
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Duration of Response Assessed by BICR
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Progression Free Survival(PFS) Assessed by BICR
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Objective Response Rate Assessed by Investigator
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Disease Control Rate Assessed by Investigator
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Duration of Response Assessed by Investigator
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Progression Free Survival(PFS) Assessed by Investigator
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Overall Survival (OS)
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Number of Participants With Adverse Events
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Number of Participants With Serious Adverse Events
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Number of Participants With Adverse Events Leading to Discontinuation
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Death Summary
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Number of Participants With Clinical Laboratory Abnormalities in Thyroid Tests
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jan 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- BMS Clinical Trial InformationLink provided by the sponsor.
- BMS Clinical Trial Patient RecruitingLink provided by the sponsor.
Related trials for Hepatocellular Carcinoma
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
65 sites in 17 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Nivolumab and Relatlimab in people with Hepatocellular Carcinoma and Hepatoma, run by Bristol-Myers Squibb at 65 sites in 17 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 65 sites in China, Japan, Spain, Brazil, France and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 Oct 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective Response Rate(ORR) Assessed by BICR (time frame: From randomization to primary completion date (Approximately 29.5 Months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2026.